Supernus Inc (SUPN) Stock
Key stats
- Market cap
- $6.12B
- EPS (TTM)
- -$0.76
- Volume
- Loading
- 52-week high
- $59.68
- 52-week low
- $25.92
Source: third-party data provider, as of November 13, 2026
Compare with SUPN
Recent news

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
SUPN

Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals Q3 Earnings Call Highlights
SUPN

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
SUPN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 30.98
- MACD 12/26/9
- -3.81
- EMA 9 of MACD
- -2.80
- MACD histogram
- -1.02
- SMA 50
- $40.14
- Price below SMA 50
- EMA 50
- $39.05
- Price below EMA 50
- SMA 200
- $46.53
- Price below SMA 200
- EMA 200
- $45.02
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.82 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
SUPN

Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals Q3 Earnings Call Highlights
SUPN

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
SUPN

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
SUPN

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
SUPN

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
SUPN

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
SUPN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Supernus Inc
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jack A. Khattar M.B.A. | Founder, President, CEO, Secretary & Director | 1961 |
| Mr. Timothy C. Dec | Senior VP & CFO | 1959 |
| Dr. Padmanabh P. Bhatt Ph.D. | Chief Scientific Officer & Senior VP of Intellectual Property | 1957 |
| Mr. Frank Mottola | Senior VP & Chief Technology Operations Officer | 1972 |
| Dr. Jonathan Rubin M.B.A., M.D. | Senior VP of Research & Development and Chief Medical Officer | 1961 |
| Mr. Kevin T. Anderson Esq. | Compliance Officer | 1962 |
| Mr. Taylor Raiford | Senior Vice President of Sales | — |
| Dr. William Todd Horich M.B.A., Ph.D. | Senior VP & Chief Commercial Officer | 1973 |
| Dr. Bryan A. Roecklein Ph.D. | Senior VP & Chief Business Officer | 1959 |
| Mr. Jeff Bozick | Senior Vice President of Supply Chain | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 30.98
- MACD 12/26/9
- -3.81
- EMA 9 of MACD
- -2.80
- MACD histogram
- -1.02
- SMA 50
- $40.14
- Price below SMA 50
- EMA 50
- $39.05
- Price below EMA 50
- SMA 200
- $46.53
- Price below SMA 200
- EMA 200
- $45.02
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $47.00
- Average
- $60.33
- High
- $87.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -8.0 | -5.5 | ||||||||||
| 2022 | +2.6 | +0.6 | +8.8 | -13.3 | -3.5 | +3.4 | +8.2 | +8.7 | -3.4 | +2.3 | +7.0 | -3.6 |
| 2023 | +9.4 | -9.6 | -7.7 | +1.2 | -10.3 | -8.8 | +2.6 | +0.5 | -15.1 | -12.1 | +14.0 | +4.9 |
| 2024 | -0.2 | +6.6 | +10.0 | -10.2 | -9.8 | -3.1 | +12.3 | +18.9 | -10.2 | +6.5 | +7.7 | -3.1 |
| 2025 | +5.3 | -14.2 | +3.2 | +2.5 | -2.3 | -1.2 | +10.3 | +27.1 | +7.3 | +14.8 | -18.2 | +11.2 |
| 2026 | -2.6 | +12.2 | -6.2 | -6.7 | -3.5 | +3.9 | -5.9 | -3.9 | -1.6 | -0.6 | +4.6 |



